ライフサイエンスコーパス: amoxicillin

1 , and one case of anaphylaxis was noted with amoxicillin.

2 CAP combines doxycycline and the recommended amoxicillin.

3 samples of chicken from animals treated with amoxicillin.

4 lude intramuscular gentamicin (GEN) and oral amoxicillin.

5 ectrum antibiotic prescriptions, in favor of amoxicillin.

6 there is increasing acceptance of once-daily amoxicillin.

7 , 95% CI [-92.8; -32.7]) and was replaced by amoxicillin.

8 tatin > cefadroxil, cephalexin > ampicillin, amoxicillin.

9 d the combination therapy metronidazole plus amoxicillin.

10 d procaine benzylpenicillin, gentamicin, and amoxicillin.

11 wed resistance to penicillin, ampicillin and amoxicillin.

12 firmatory test for skin-related reactions to amoxicillin.

13 rative inflammation to a greater extent than amoxicillin.

14 -gentamicin and 1163 infants to receive oral amoxicillin.

15 % (n = 60/95) of them were resistant against amoxicillin.

16 daily injections and the first dose of oral amoxicillin.

17 sequential therapy (Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor

18 ant therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice d

19 ected were randomly assigned (1:1) to either amoxicillin (1 g three times daily for 7 days) or placeb

20 ,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (26

21 e risk of treatment failure with placebo vs. amoxicillin, 1.32; 95% confidence interval [CI], 1.04 to

22 ely (relative risk of death with placebo vs. amoxicillin, 1.55; 95% CI, 1.07 to 2.24; relative risk w

23 n = 103) received pantoprazole 40 mg 2x/day, amoxicillin 1000 mg 12/12 h and clarithromycin (CLARI) 5

24 n were prescribed pantoprazole 40 mg 2x/day, amoxicillin 1000 mg 12/12 h and LVX 250 mg 12/12 h, for

25 llocated to 3 treatment arms of 6 weeks: (1) amoxicillin (1000 mg/d), (2) doxycycline (200 mg/d), or

26 el was exposed to metronidazole (15 mug/mL), amoxicillin (15 mug/mL), metronidazole and amoxicillin i

27 niazid (nine), phenytoin (five), clavulanate/amoxicillin (15), and valproate (11).

28 Ten-day course of either amoxicillin (1500 mg/d) or placebo administered in 3 dos

29 ial therapy (esomeprazole 40 mg twice daily, amoxicillin 1g twice daily for 5 days followed by esomep

30 days allowing discharge of the patient with amoxicillin (2 g tid per os).

31 imethoprim-sulfamethoxazole, penicillin, and amoxicillin (22%, 8/37 each).

32 A dose of 500 mg of amoxicillin 3 times per day for 7 days and 200 mug of bu

33 icrobials tested for susceptibility pattern; amoxicillin 38.7%, ciprofloxacin 25.8%, chloramphinicol

34 whom received subsequent full treatment with amoxicillin; 49 of these 55 participants (89.1%) reporte

35 otics were the following: tetracycline, 79%; amoxicillin, 78%; cephalosporins, 31%; trimethoprim, 20%

36 Antibiotics, primarily amoxicillin (80%) with aminoglycosides (48%), were presc

37 Among antibiotics, amoxicillin (97 cases), other penicillins (four cases),

38 for amoxicillin vs 36 of 107 (33.6%) for no amoxicillin (adjusted odds ratio, 0.99; 95% confidence i

39 ly reduced by doxycycline, azithromycin, and amoxicillin alone or in combination with metronidazole,

40 as well as Campylobacter rectus (except for amoxicillin alone).

41 rowth inhibition were detected compared with amoxicillin alone.

42 nsity score-matched adults treated with oral amoxicillin (amoxicillin cohort = 178 179 prescriptions)

43 mproved bactericidal efficacy in addition to amoxicillin, ampicillin and cefotaxime.

44 -lactam antibiotics, including penicillin-G, amoxicillin, ampicillin, and cefazolin, are protected fr

45 recorded for selected antibiotics, including amoxicillin, ampicillin, lomefloxacin, and ofloxacin.

46 Use of amoxicillin/ampicillin may lead to overgrowth of K. pneu

47 beta-lactam antibiotics ampicillin (Amp) and amoxicillin (Amx) are linked to a monofunctionalized ent

48 igated for the quantitative determination of amoxicillin (AMX) as well as qualitative analysis of met

49 he adjunctive use of metronidazole (MTZ) and amoxicillin (AMX) in the treatment of smokers and non-sm

50 r test (E-test) for clarithromycin (CLR) and amoxicillin (AMX).

51 s and is inhibited by azithromycin (AZM) and amoxicillin (AMX).

52 Amoxicillin, an antimicrobial agent with similar indicat

53 nts treated with 40 mg pantoprazole, 1000 mg amoxicillin and 500 mg clarithromycin, twice daily for 7

54 In group A, patients received 375 mg amoxicillin and 500 mg metronidazole three times per day

55 received either systemic antibiotics (375 mg amoxicillin and 500 mg metronidazole, three times daily)

56 An antibiotherapy associating intravenous amoxicillin and amoxicillin/clavulanate was administered

57 Both amoxicillin and ampicillin produce [M + H](+), [M + CH3O

58 .7%) and 21 of 261 (8.0%) of patients in the amoxicillin and benzyl penicillin arms, respectively (ri

59 nferiority margin of risk difference between amoxicillin and benzyl penicillin groups was prespecifie

60 rug regimens of a proton-pump inhibitor plus amoxicillin and clarithromycin are significantly less ef

61 a course of empirical systemic antibiotics (amoxicillin and clavulanic acid, 375 mg, to be taken 3 t

62 n either TEM or SHV results in resistance to amoxicillin and clavulanic acid, an important clinical b

63 Oral amoxicillin and cotrimoxazole were widely available at l

64 dden death among those who concurrently used amoxicillin and CYP3A inhibitors or those currently usin

65 tamicin (reference), 76 (10%) of those given amoxicillin and gentamicin (risk difference with referen

66 micin, 816 (751 per protocol) were allocated amoxicillin and gentamicin, and 817 (753 per protocol) w

67 association between recent use of ampicillin/amoxicillin and KPLA.

68 In cases with severe periodontitis (N = 24), amoxicillin and metronidazole (AM) were prescribed for 7

69 In cases with severe periodontitis (n = 24), amoxicillin and metronidazole (AM) were prescribed for 7

70 The systemic use of combined amoxicillin and metronidazole (AMX/MET) as an adjunctive

71 The combination of Amoxicillin and metronidazole (AMX/MET) as an adjunctive

72 effect of the concomitant administration of amoxicillin and metronidazole adjunctive to SRP in adult

73 antimicrobial therapy using a combination of amoxicillin and metronidazole as an adjunct to SRP can e

74 rgical periodontal treatment associated with amoxicillin and metronidazole in individuals with aggres

75 hanical treatment associated with the use of amoxicillin and metronidazole led to an improvement in a

76 ning, surgery, and systemically administered amoxicillin and metronidazole or as GR (n = 30) based on

77 eceived plaque control and root planing plus amoxicillin and metronidazole or to a control treatment

78 ival periodontal pathogens resistant to both amoxicillin and metronidazole, which were mostly either

79 effects were displayed by the combination of amoxicillin and metronidazole.

80 g/L, with a post hoc combination of data for amoxicillin and metronidazole.

81 nd root planing, and a 7-day prescription of amoxicillin and metronidazole.

82 and ZNF300 predicted skin test positivity to amoxicillin and other penicillins but not to cephalospor

83 s and the other species were as expected for amoxicillin and penicillin, with all B. anthracis cultur

84 nts, compared with only 3.2% and 5.6% in the amoxicillin and placebo arms, respectively.

85 To determine the effectiveness of amoxicillin and topical budesonide in acute maxillary si

86 15-22) for levofloxacin, 3% (95% CI 2-5) for amoxicillin, and 4% (95% CI 2-5) for tetracycline.

87 Clarithromycin, amoxicillin, and a pump proton inhibitor are the most co

88 common antibiotics (amoxicillin-clavulanate, amoxicillin, and azithromycin).

89 The efficacy of oral doxycycline, amoxicillin, and cefuroxime axetil for treating Lyme dis

90 ncing procedure to: 14 days of lansoprazole, amoxicillin, and clarithromycin (standard therapy); 5 da

91 of 3 treatment groups: 14-day lansoprazole, amoxicillin, and clarithromycin (triple therapy); 5-day

92 consisting of a proton pump inhibitor (PPI), amoxicillin, and clarithromycin.

93 %, and 60% for the toothbrushing, extraction-amoxicillin, and extraction-placebo groups, respectively

94 rgical site for a longer period of time than amoxicillin, and patients taking azithromycin exhibited

95 i isolates to metronidazole, clarithromycin, amoxicillin, and tetracycline was performed using agar d

96 infants (2.8%) had treatment failure in the amoxicillin arm and 25 (5.9%) in the placebo arm (risk d

97 fants fulfilled per protocol criteria in the amoxicillin arm and 426 in the placebo arm.

98 arm died, whereas no deaths occurred in the amoxicillin arm.

99 s were tested in vitro for susceptibility to amoxicillin at 8 mg/L, clindamycin at 4 mg/L, doxycyclin

100 up to assess reactions to subsequent use of amoxicillin at the time of illness in cases with negativ

101 A label-free biosensing strategy for amoxicillin (AX) allergy diagnosis based on the combinat

102 vel intracellular targets for haptenation by amoxicillin (AX) and their cellular fate.

103 ivity reactions to clavulanic acid (CLV) and amoxicillin (AX), probably due to their increased prescr

104 Relative to amoxicillin, azithromycin was associated with an increas

105 c gradient strip susceptibility testing with amoxicillin, azithromycin, clindamycin, ciprofloxacin, a

106 ulting from a single dose of azithromycin or amoxicillin before surgical placement of one-stage denta

107 m [dfrA1, dfrA5, dfrA7, dfrA12, and dfrA15], amoxicillin [bla(TEM)], streptomycin [strA-strB], chlora

108 In the amoxicillin, cefdinir, and placebo groups, 88.7%, 90.9%,

109 e, with severe acute malnutrition to receive amoxicillin, cefdinir, or placebo for 7 days in addition

110 The isolates had low MICs to amoxicillin, cefotaxime, ceftriaxone, doxycycline, linez

111 lates tested were susceptible to penicillin, amoxicillin, cefotaxime, cefuroxime, erythromycin, chlor

112 The beta-lactam antibiotics ampicillin, amoxicillin, cephalexin and cefadroxil, the antineoplast

113 llin skin testing (PST) with or without oral amoxicillin challenge was the main intervention describe

114 idazole (sequential); or 5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole (concomit

115 (standard therapy); 5 days of lansoprazole, amoxicillin, clarithromycin, and metronidazole (concomit

116 In contrast, amoxicillin clavulanate and troglitazone did not interfe

117 The most commonly implicated drugs were amoxicillin-clavulanate (21 of 96; 22%), diclofenac (6%)

118 rial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of plac

119 rial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of plac

120 Receipt of amoxicillin-clavulanate (HR, 6.48; 95% CI, 1.43-29.4; P

121 timicrobials remained very active, including amoxicillin-clavulanate (MIC90s, < or =0.25 microg/ml),

122 1/145 isolates tested that were resistant to amoxicillin-clavulanate (resistance breakpoint >/= 16/8

123 lin-tazobactam [3.0/0.375 g q6 hours] +/- PO amoxicillin-clavulanate [800 mg/114 mg q12 hours]), each

124 ibiotics, including high-dose amoxicillin or amoxicillin-clavulanate and 3 injections of ceftriaxone;

125 e to a wide range of beta-lactams (including amoxicillin-clavulanate and cefotaxime) were isolated fr

126 beta-Lactam agents (amoxicillin-clavulanate and cefpodoxime-proxetil) are no

127 sceptible to ciprofloxacin, chloramphinicol, amoxicillin-clavulanate and ceftriaxone.

128 5:02, allo-purinol and HLA-B*58:01, and both amoxicillin-clavulanate and nevirapine with multiple cla

129 ulence, and resistance of M. tuberculosis to amoxicillin-clavulanate and vancomycin.

130 Overall 35,252 patients received amoxicillin-clavulanate as outpatients, and DILI occurre

131 oxifloxacin, levofloxacin, ciprofloxacin, or amoxicillin-clavulanate at outpatient visits.

132 Previously it was shown that amoxicillin-clavulanate can provide clavulanate inhibiti

133 ve as standard IV piperacillin-tazobactam/PO amoxicillin-clavulanate dosed multiple times daily for t

134 of virulence and increased susceptibility to amoxicillin-clavulanate during the chronic phase of infe

135 s of age, with acute otitis media to receive amoxicillin-clavulanate either for a standard duration o

136 Empirical therapy with itraconazole and amoxicillin-clavulanate failed to resolve the infection.

137 age with acute otitis media, treatment with amoxicillin-clavulanate for 10 days tended to reduce the

138 Children who were treated with amoxicillin-clavulanate for 5 days were more likely than

139 omly allocated to receive either 40 mg/kg of amoxicillin-clavulanate or a placebo mixture per day for

140 th the use of stringent criteria, to receive amoxicillin-clavulanate or placebo for 10 days.

141 llei had subpopulations with ceftazidime and amoxicillin-clavulanate susceptibilities that differed a

142 acin-colistin eardrops (76 children) or oral amoxicillin-clavulanate suspension (77) or to undergo in

143 s also lower among the children treated with amoxicillin-clavulanate than among those who received pl

144 ays were lower for the children treated with amoxicillin-clavulanate than for those who received plac

145 Compared with amoxicillin-clavulanate treatment, the use of azithromyc

146 sms using nonsusceptibility to cefoxitin and amoxicillin-clavulanate was less specific than APBA test

147 Amoxicillin-clavulanate was the most commonly implicated

148 The MICs of amoxicillin-clavulanate were higher than that of ampicil

149 Among the children who received amoxicillin-clavulanate, 35% had initial resolution of s

150 ed prescribing data on 3 common antibiotics (amoxicillin-clavulanate, amoxicillin, and azithromycin).

151 azithromycin and clarithromycin, quinolones, amoxicillin-clavulanate, and second- and third-generatio

152 esponding values were 20%, 41%, and 67% with amoxicillin-clavulanate, as compared with 14%, 36%, and

153 scribed broad-spectrum antibiotics including amoxicillin-clavulanate, cephalosporins, and macrolides.

154 flucloxacillin, ximelagatran, lapatinib, and amoxicillin-clavulanate.

155 illin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate.

156 were more common among children who received amoxicillin-clavulanate.

157 A total of 117 patients with amoxicillin/clavulanate (74.1%) and 91 with placebo (59.

158 The implicated agents included amoxicillin/clavulanate (n = 3), temozolomide (n = 3), v

159 An oral fluoroquinolone plus amoxicillin/clavulanate (or plus clindamycin if penicill

160 The patients were randomized to receive amoxicillin/clavulanate 500/125 mg three times a day or

161 exacerbations of mild-to-moderate COPD with amoxicillin/clavulanate is more effective and significan

162 rapy associating intravenous amoxicillin and amoxicillin/clavulanate was administered.

163 Amoxicillin/clavulanate was the most frequently prescrib

164 /beta-lactamase inhibitor combinations (e.g. amoxicillin/clavulanate) in the treatment of serious bac

165 orally administered antibiotics, ampicillin, amoxicillin/clavulanate, and ciprofloxacin exhibited mar

166 rates of nonsusceptibility were observed for amoxicillin/clavulanate, erythromycin, and levofloxacin

167 otics, defined for this study as quinolones, amoxicillin/clavulanate, second- and third-generation ce

168 and 100% susceptible in vitro to ampicillin, amoxicillin/clavulanate, vancomycin, and teicoplanin.

169 e successfully treated with further cycle of amoxicillin/clavulanate.

170 underwent nonoperative management (NOM) with amoxicillin/clavulanate.

171 oli from group B showed higher resistance to amoxicillin-clavulanic acid (P = .03), trimethoprim-sulf

172 ay in patients treated with an active BLBLI (amoxicillin-clavulanic acid [AMC] and piperacillin-tazob

173 c bacteria, all cultures were susceptible to amoxicillin-clavulanic acid and gentamicin and 99% (one

174 y supported the use of either norfloxacin or amoxicillin-clavulanic acid in the treatment of small bo

175 class II and susceptibility to coamoxiclav (amoxicillin-clavulanic acid) induced DILI.

176 ies, acceptable agreement was also found for amoxicillin-clavulanic acid, linezolid, minocycline, and

177 oral ciprofloxacin (750 mg twice daily) plus amoxicillin/clavulanic acid (1,000 mg twice daily).

178 en for a minimum of 5 days, after which oral amoxicillin/clavulanic acid (875/125 mg every 12 h) coul

179 an extended-spectrum beta-lactam antibiotic amoxicillin/clavulanic acid and a first-generation cepha

180 Positive responses have been reported with amoxicillin/clavulanic acid, clindamycin, metronidazole,

181 atched adults treated with oral amoxicillin (amoxicillin cohort = 178 179 prescriptions).

182 RD compared to 46 (0.026%) among the matched amoxicillin cohort.

183 ith acute rhinosinusitis, a 10-day course of amoxicillin compared with placebo did not reduce symptom

184 In secondary analyses, amoxicillin decreased the risk of transfer to inpatient

185 (an antimicrobial metabolite of cephapirin), amoxicillin, desfuroylceftiofur cysteine disulfide (DCCD

186 tom severity (1.69 with placebo vs 1.62 with amoxicillin; difference -0.07 [95% CI -0.15 to 0.007]; p

187 s were in-vitro susceptible to penicillin G, amoxicillin, doxycycline, rifampicin and gentamicin.

188 tant therapy); or 5 days of lansoprazole and amoxicillin followed by 5 days of lansoprazole, clarithr

189 cin (triple therapy); 5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromyc

190 lpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days (group C); or injectable gentamic

191 rence group); injectable gentamicin and oral amoxicillin for 7 days (group B); injectable procaine be

192 or injectable gentamicin for 2 days and oral amoxicillin for 7 days (group D).

193 pothesis that ambulatory treatment with oral amoxicillin for 7 days was equivalent (similarity margin

194 e aimed to compare the benefits and harms of amoxicillin for acute lower-respiratory-tract infection

195 rica guidelines that recommend ampicillin or amoxicillin for children hospitalized with community-acq

196 When used to quantify amoxicillin, good distinction is achieved between soluti

197 icantly higher in the placebo (84%) than the amoxicillin group (33%) (P<0.0001).

198 ecovery occurred in 65.9% of children in the amoxicillin group (790 of 1199) and in 62.7% of children

199 n 76% of the placebo group versus 15% of the amoxicillin group (P<0.001).

200 0% in the placebo group and 4% and 6% in the amoxicillin group (P=0.05 and P=0.07, respectively).

201 compared with 221 (19%) infants in the oral amoxicillin group (risk difference -2.6%, 95% CI -6.0 to

202 een groups on day 3 (decrease of 0.59 in the amoxicillin group and 0.54 in the control group; mean di

203 1038 patients were assigned to the amoxicillin group and 1023 to the placebo group.

204 interleukin (IL)-6 and IL-8 in GCF than the amoxicillin group and exhibited significantly lower leve

205 patients in the placebo group and one in the amoxicillin group needed to be admitted to hospital; no

206 mptoms were significantly less common in the amoxicillin group than in the placebo group (162 [15.9%]

207 rrhoea were significantly more common in the amoxicillin group than in the placebo group (number need

208 ported symptom improvement at day 3 (37% for amoxicillin group vs 34% for control group; P = .67) or

209 ed 1 or more symptomatic treatments (94% for amoxicillin group vs 90% for control group; P = .34).

210 nsfer to inpatient care by 14% (26.4% in the amoxicillin group vs. 30.7% in the placebo group; risk r

211 cin group and 1145 (98%) infants in the oral amoxicillin group.

212 Patients who took amoxicillin had no increase in the risk of death during

213 l containing cluster for both ampicillin and amoxicillin has a clear tendency to rise with sample kee

214 Although amoxicillin has a significant impact on bacteremia resul

215 Amoxicillin has a significant impact on the incidence, n

216 mycin sensitivity was present in 30(64%) and amoxicillin in 45(98%), respectively.

217 of how Mtb responds to beta-lactams such as Amoxicillin in combination with Clav (referred as Augmen

218 , amoxicillin (15 mug/mL), metronidazole and amoxicillin in combination, doxycycline (2 mug/mL), and

219 ial failed to show equivalence of placebo to amoxicillin in the management of isolated fast breathing

220 .26) or among those who were currently using amoxicillin (incidence-rate ratio, 1.18; 95 percent conf

221 Prescribing of ampicillin/amoxicillin increased following guideline publication, b

222 NTHi 86-028NP bla was resistant to amoxicillin killing in biofilm studies in vitro; however

223 T and levofloxacin-containing therapy (PPI + amoxicillin + levofloxacin).

224 13 to 0.15]), but differed at day 7 favoring amoxicillin (mean difference between groups of 0.19 [95%

225 ruple therapy (proton pump inhibitor [PPI] + amoxicillin + metronidazole + clarithromycin [PAMC]) and

226 6-2000-fold lower than the five antibiotics, amoxicillin, metronidazole, levofloxacin, tetracyclin, a

227 ans, were resistant in vitro to doxycycline, amoxicillin, metronidazole, or clindamycin, in 55%, 43.3

228 pplemented with increasing concentrations of amoxicillin, metronidazole, or their combination and inc

229 mes of periodontal therapy supplemented with amoxicillin-metronidazole during either the non-surgical

230 , microbiologic, and immunologic benefits of amoxicillin/metronidazole (AM) when performing full-mout

231 It may be concluded that amoxicillin/metronidazole improves clinical and microbio

232 Amoxicillin/metronidazole used as an adjunct to the FMUD

233 he enzyme activity through the estimation of amoxicillin minimum inhibitory concentration on a subset

234 ere allocated randomly to receive either 2 g amoxicillin (n = 7) or 500 mg azithromycin (n = 6) befor

235 ale; 78% with white race) were randomized to amoxicillin (n = 85) or placebo (n = 81); 92% concurrent

236 pond to the major resistances (tetracycline, amoxicillin) of E. coli.

237 and in recognition and treatment (with oral amoxicillin) of suspected neonatal respiratory infection

238 g alone can be effectively treated with oral amoxicillin on an outpatient basis when referral to a ho

239 h 2 or more antibiotics, including high-dose amoxicillin or amoxicillin-clavulanate and 3 injections

240 aged 2-59 months were randomized to receive amoxicillin or benzyl penicillin and followed up for the

241 cantly lower for samples treated with either amoxicillin or metronidazole compared with controls (P <

242 riple therapy (PPI + clarithromycin + either amoxicillin or metronidazole) is restricted to areas wit

243 stant to the Malawian first-line antibiotics amoxicillin or penicillin, chloramphenicol, and co-trimo

244 licated severe acute malnutrition to receive amoxicillin or placebo for 7 days.

245 ere randomly assigned to receive either oral amoxicillin or placebo twice daily for 7 days.

246 , plus clarithromycin or metronidazole, plus amoxicillin or tetracycline, with or without bismuth, in

247 Heart Association (AHA)-recommended dose of amoxicillin or to a placebo.

248 enicillin, ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate.

249 caused by isoniazid, phenytoin, clavulanate/amoxicillin, or valproate occurring since 1994.

250 tructurally related beta-lactam antibiotics (amoxicillin, oxacillin, penicillin G).

251 y associated with allergy to penicillins and amoxicillin (P = 6.0 x 10(-4) and P = 4.0 x 10(-4), resp

252 oup (n = 12), which received FMUD and 375 mg amoxicillin plus 250 mg metronidazole for 7 days.

253 riodontal treatment supplemented with 375 mg amoxicillin plus 500 mg metronidazole, three times daily

254 culous cholecystitis and who received 2 g of amoxicillin plus clavulanic acid 3 times a day while in

255 iotics, lack of postoperative treatment with amoxicillin plus clavulanic acid did not result in a gre

256 Amoxicillin plus metronidazole did not significantly aff

257 nced periodontitis benefit specifically from amoxicillin plus metronidazole given as an adjunct to fu

258 It has been suggested that prescription of amoxicillin plus metronidazole in the context of periodo

259 mycetemcomitans had no specific benefit from amoxicillin plus metronidazole.

260 toothbrushing and to determine the impact of amoxicillin prophylaxis on single-tooth extraction.

261 trolled study was to determine the impact of amoxicillin prophylaxis on the incidence, nature, and du

262 thbrushing, (2) single-tooth extraction with amoxicillin prophylaxis, or (3) single-tooth extraction

263 When pneumonia is not suspected clinically, amoxicillin provides little benefit for acute lower-resp

264 s suggest that a single prophylactic dose of amoxicillin reduces early implant complications, but it

265 Penicillin or amoxicillin remain the treatments of choice, and recomme

266 reas at day 7 more participants treated with amoxicillin reported symptom improvement (74% vs 56%, re

267 romycin resistance in 159/531 (30%) persons, amoxicillin resistance in 10/531 (2%) persons, and levof

268 Exceptionally high amoxicillin resistance was observed among Gram positive

269 Amoxicillin resulted in a significant decrease in positi

270 harmaceutical ingredients (APIs) ampicillin, amoxicillin, rifampicin, isoniazid, ethambutol, and pyra

271 h procaine benzylpenicillin, gentamicin, and amoxicillin (risk difference with reference 1.1, -2.3 to

272 Amoxicillin shows two peaks at 0.909 cm(2)/(V s) and 0.9

273 Ampicillin/amoxicillin therapy started within the past 30 days was

274 ntibiotics (500 mg metronidazole plus 375 mg amoxicillin three times per day for 7 days) during the f

275 from studies showing noninferiority of oral amoxicillin to benzyl penicillin for severe pneumonia ma

276 Our findings confirm noninferiority of amoxicillin to benzyl penicillin, provide estimates of r

277 ered from the surface-associated bacteria of amoxicillin-treated animals; only NTHi 86-028NP bla was

278 dren presenting with a rash in the course of amoxicillin treatment are currently unknown.

279 We aimed to assess whether oral amoxicillin treatment for fast breathing, in the absence

280 studies in vitro; however, it was cleared by amoxicillin treatment in vivo, whereas NTHi 86-028NP was

281 ylpenicillin-gentamicin once per day or oral amoxicillin treatment twice per day for 7 days.

282 icin once a day for 7 days (reference); oral amoxicillin twice daily and intramuscular gentamicin onc

283 micin once a day for 2 days followed by oral amoxicillin twice daily for 5 days.

284 entamicin once per day for 2 days, then oral amoxicillin twice per day for 5 days (group C).

285 tramuscular gentamicin once per day and oral amoxicillin twice per day for 7 days (group B) or intram

286 ven hybrid therapy (40 mg omeprazole and 1 g amoxicillin, twice daily for 14 days; 500 mg clarithromy

287 treated with 40 mg pantoprazole and 1000 mg amoxicillin, twice daily for the first 5 days, followed

288 vestigate the association between ampicillin/amoxicillin use and KPLA in Taiwan.

289 ing 10 or more days were 29 of 100 (29%) for amoxicillin vs 36 of 107 (33.6%) for no amoxicillin (adj

290 d rising to 13.5% and 16.8% by day 14 in the amoxicillin vs benzyl penicillin groups, respectively.

291 as higher for immediate use of ampicillin or amoxicillin vs placebo (73% vs 60%; pooled rate differen

292 hood of nutritional recovery (risk ratio for amoxicillin vs. placebo, 1.05; 95% confidence interval [

293 2.77 +/- 0.90 mug/mL, respectively, whereas amoxicillin was below the limit of detection.

294 concentration at 90% [MIC90] 0.25 mg/L), and amoxicillin was most active against S. intermedius (MIC9

295 Although amoxicillin was predominantly prescribed, only ofloxacin

296 Both doxycycline and amoxicillin were able to reduce acute dermatolymphangioa

297 children referred with suspected allergy to amoxicillin were approached.

298 kbone and its conjugates with ampicillin and amoxicillin were synthesized.

299 tolerance to subsequent full treatment with amoxicillin, while 6 (10.9%) developed nonimmediate cuta

300 The MICs of amoxicillin with clavulanate, ampicillin, chloramphenico

301 djusted OR associating the use of ampicillin/amoxicillin within the past 30 days with KPLA was 3.5 (9